Top

Published in:

01-01-2010 | Original Article

The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis

Authors: Esra Baskin, Seza Ozen, Nilgun Çakar, Umut S. Bayrakci, Erkan Demirkaya, Aysin Bakkaloglu

Published in: Pediatric Nephrology | Issue 1/2010

Abstract

Cyclophosphamide (CYC) has been the landmark in the treatment of lupus nephritis. However, long-term treatment with CYC is associated with significant side effects. We aimed to evaluate the efficacy of short-term intravenous (IV) CYC treatment as a remission induction treatment followed by azathioprine (AZA) or mycophenolate mofetil (MMF) as a maintenance treatment. Twenty patients (18 girls) with biopsy-proven class III (5) and IV (15) lupus nephritis were included in to the study. Detailed clinical and laboratory data and patient outcomes were evaluated. All patients received three methylprednisolone (MP) IV pulses, followed by oral prednisone 0.5−1 mg/kg per day and one IV pulse of CYC per month for 6 months. Azathioprine was started as a remission-maintaining treatment. In ten of 20 patients, treatment was switched to MMF. The mean age at the time of diagnosis was 16.11 ± 3.49 years, and the mean duration of follow-up was 49.6 ± 27 months. Fourteen patients (70%) had complete remission, three (15%) had partial remission, one (5%) continued to have active disease, and two (10%) progressed to end-stage renal disease. Nine of the patients (45%) with complete remission had received AZA, and switching to MMF increased complete remission rate (additional five patients; 25%). In conclusion, short-term (6-month) IV bolus CYC treatment followed by AZA is a safe and effective treatment in children with severe lupus nephritis, and using MMF increases remission rate in resistant cases.

Niaudet P (2000) Treatment of lupus nephritis in children. Pediatr Nephrol 14:158–166PubMed

Perfumo F, Martini A (2005) Lupus nephritis in children. Lupus 14:83–88PubMed

Bakkaloglu A (2001) Lupus nephropathy in children. Nephrol Dial Transplant 16(Suppl 6):126–128PubMed

Ranchin B, Fargue S (2007) New treatment strategies for proliferative lupus nephritis: keep children in mind. Lupus 16:684–691PubMed

Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136:243–247

Vasoo S, Hughes GR (2005) Theory, targets and therapy in systemic lupus erythematosus. Lupus 14:181–188PubMed

Felson DT, Anderson J (1984) Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 311:1528–1533PubMed

Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC (2004) Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 43:197–208PubMed

Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619

10.

Boumpas DT, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745PubMed

11.

Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 125:549–557PubMed

12.

Illei GG, Austin HA, Crane M, Collinins L, Gourley MF, Yarboro CH (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248–257PubMed

13.

Adams A, MacDermott EJ, Lehman TJA (2006) Pharmacotherapy of lupus nephritis in children. Drugs 66:1191–1207PubMed

14.

Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131

15.

Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14:s2–s8PubMed

16.

Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Ji YL, Lau CS, Wong AKM, Tong MKL, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162PubMed

17.

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228PubMed

18.

Fu YF, Liu GL (2001) Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol 55:318–321PubMed

19.

Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A (2001) Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 28:2103–2108PubMed

20.

Paredes A (2007) Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol 22:1077–1082PubMed

21.

Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus ertythematosus revisited. Kidney Int 65:521–530

22.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMed

23.

Wong SN, Tse KC, Lee TL, Lee KW, Chim S, Lee KP, Wai-Po Chu R, Chan W, Fong KW, Hui J, Po-Siu Li S, Yeung PS, Yuen SF, Chi-Hang Ho A, Chuk-Kwan Leung L, Luk D, Tong PC, Chan SY, Cheung HM, Chow CM, Lau D (2006) Lupus nephritis in Chinese children- a territory-wide cohort study in Hong Kong. Pediatr Nephrol 21:1104–1112PubMed

24.

Bogdanovic R, Nikolic V, Pasic S, Dimitrijevic J, Lipkovska-Markovic J, Eric-Marinkovic J, Ognjanovic M, Minic A, Stajic N (2004) Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 19:36–44PubMed

25.

Lehman TJA, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136:243–247

26.

Emre S, Bilge I, Sirin A, Kilicaslan I, Nayir A, Oktem F, Uysal V (2001) Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 87:118–126PubMed

27.

Vachvanichsanong P, Dissaneewate P, Winn T (2004) Intravenous cyclophosphamide for lupus nephritis in Thai children. Scand J Rheumatol 33:339–342

28.

Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, Flis R, Pirani C, Appel GB (1994) Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five year study. Clin Nephrol 42:71–78

29.

Dixit MP, Bracamonte E, Dixit N (2004) Intravenous cyclophosphamide-resistant systemic lupus erythematosus in Arizona. Pediatr Nephrol 19:738–743PubMed

30.

Beimler JHM, Andrassy K (2004) Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? Pediatr Nephrol 19:949–955PubMed

31.

Brunner HI, Bishnoi A, Barron AC, Houk LJ, Ware A, Farhey Y, Mongey AB, Strife CF, Graham TB, Passo MH (2006) Disease outcomes and ovarian function of childhood onset systemic lupus erythematosus. Lupus 15:198–206PubMed

32.

Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk of sustained amenorrhea in patients with SLE treated with intermittant pulse cyclophosphamide therapy. Ann Intern Med 119:366–369PubMed

33.

Houssiau F (2007) Thirty years of cyclophosphamide; assessing the evidence. Lupus 16:212–216PubMed

34.

Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2009) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose versus high-dose intravenous cyclophosphamide. Ann Rheum Dis. doi:https://doi.org/10.1136/ard.2008.102533

35.

Fujinaga S, Kaneko K, Ohtomo Y, Murakami H, Takada M, Akashi S, Hira M, Yamashiro Y (2005) Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Pediatr Nephrol 20:1500–1503PubMed

36.

Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, Martini A, Ravelli A (2006) A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 54:2989–2996PubMed

37.

Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50:2559–2568PubMed

38.

Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E (2002) Long-term follow up of childhood lupus nephritis. J Rheumatol 29:2635–2642PubMed

39.

Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980PubMed

40.

Fujinaga S, Ohtomo Y, Hara S, Umino D, Someya T, Shimizu T, Kaneko K (2008) Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. Pediatr Nephrol 23:1877–1882PubMed

41.

Pecoraro C, Malgieri G, D’Armiento M, Balletta MM, Nuzzi F, Caropreso M (2005) Treatment of childhood lupus nephritis with mycophenolate mofetil: clinical and histopathological study. J Am Soc Nephrol 16:557A

42.

MacDermott EJ, Adams A, Lehman TJA (2007) Systemic lupus erythematosus in children: current and emerging therapies. Lupus 16:677–683PubMed

Title: The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis
Authors: Esra Baskin
Seza Ozen
Nilgun Çakar
Umut S. Bayrakci
Erkan Demirkaya
Aysin Bakkaloglu
Publication date: 01-01-2010
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 1/2010
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-009-1291-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Cellular stress-response modulators in the acute rat model of peritoneal dialysis

Severe atypical HUS caused by CFH S1191L—case presentation and review of treatment options

Acute glomerulonephritis associated with pneumonia: a review of three cases

Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease

A rare cause of chronic renal failure in a girl with elevated serum uric acid level: answer

Outcomes of kidney transplant tourism in children: a single center experience